NCT04728698

Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress

Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sorrento Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, randomized controlled, multicenter study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care (SOC) treatments for COVID-19 infection in hospitalized subjects with ARD/ARDS.

Conditions

• Covid19
• ARDS

Interventions

Type	Name	Description
DRUG	COVI-MSC	1 x 10\^6 MSCs/kg or 1.5 x 10\^6 MSCs/kg, depending on CRP level
DRUG	Placebo	Equivalent volume of placebo will be administered

Timeline

• Start date: 2021-03-01
• Primary completion: 2021-09-01
• Completion: 2021-09-01
• First posted: 2021-01-28
• Last updated: 2021-09-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study